Please login to the form below

Living with NASH: An Unexpected Diagnosis

Published in eyeforpharma November 2017 by Mariel Metcalfe

With no current licensed treatments and more than 20 compounds in phase II and III, the liver disease non-alcoholic steatohepatitis (NASH) represents a huge opportunity for pharma companies – if they understand patient needs.

As our waistlines thicken and our activity levels decrease, another chronic illness threatens to disturb our comfortable lifestyles. And, because it’s relatively unknown, diagnosis comes as a shock to patients, who usually associate liver disease with heavy consumption of alcohol...

Read the full article: 
https://www.researchpartnership.com/news/2017/11/living-with-nash-an-unexpected-diagnosis/


1st December 2017

Share

Tags

Company Details

Research Partnership

+44 (0)20 8069 5000

Contact Website

Address:
Chester House
Fulham Green
81-83 Fulham High Street
London
SW6 3JW
United Kingdom

Latest content on this profile

RP Investigates - Virtual Q&A session:
Living with Lupus
Research Partnership
Webcast:
Demand assessment
Research Partnership
White paper:
Are we prepared for the influx of CAR-Ts?
Research Partnership
New syndicated patient report -
Living with Lupus US
Research Partnership
Video:
Emotion AI
Research Partnership
Report:
Mexico’s drug market access landscape shake-up: What does it mean for pharma?
Research Partnership